Literature DB >> 6083690

Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid.

G Póvoa, A Roovete, K Hall.   

Abstract

A radioimmunoassay was developed for somatomedin-binding protein isolated from human amniotic fluid. The mean level in amniotic samples from 20-22 week of gestation was high, 51 micrograms/ml. Human serum and serum fraction gave dose-response curves superimposable on that for the pure amniotic binding protein. Gel chromatography of serum at neutral pH disclosed immunoreactive binding protein only in fractions with a molecular size of 35 000 corresponding to elution volume for the low molecular form somatomedin-binding protein. The mean levels (mean and range) of immunoreactive somatomedin-binding protein in cord blood (191 ng/ml, 55-1698 ng/ml) and in diabetic patients with uraemia (97 and 51-174 ng/ml) were 5- to 10-fold elevated above those of healthy adults (23 and 18-36 ng/ml). In acromegaly the levels decreased with increasing GH production (r = -0.77; P less than 0.005). In adult patients with GH deficiency the levels were 2-fold elevated in comparison with healthy subjects. Apart from patients with uraemia a negative correlation was found in adults between the levels of immunoreactive binding protein and immunoreactive IGF-I which reflect the GH production (r = -0.81, P less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6083690     DOI: 10.1530/acta.0.1070563

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  41 in total

Review 1.  The insulin-like growth factor family of ligands, receptors, and binding proteins.

Authors:  R F Krywicki; D Yee
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 2.  Growth factors in the ovary.

Authors:  G Giordano; A Barreca; F Minuto
Journal:  J Endocrinol Invest       Date:  1992-10       Impact factor: 4.256

3.  Long-term GH treatment of GH-deficient adults: comparison between one and two daily injections.

Authors:  C Höybye; M Rudling
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

Review 4.  Somatomedins: chemical and functional characteristics of the different molecular forms.

Authors:  A Barreca; F Minuto
Journal:  J Endocrinol Invest       Date:  1989-04       Impact factor: 4.256

5.  The role of IGF-I and IGFBP-1 status and secondary hyperparathyroidism in relation to osteoporosis in elderly Swedish women.

Authors:  H Salminen; M Sääf; H Ringertz; L E Strender
Journal:  Osteoporos Int       Date:  2007-09-14       Impact factor: 4.507

6.  Hunger-satiety signals in patients with Graves' thyrotoxicosis before, during, and after long-term pharmacological treatment.

Authors:  Sven Röjdmark; Jan Calissendorff; Olle Danielsson; Kerstin Brismar
Journal:  Endocrine       Date:  2005-06       Impact factor: 3.633

7.  Explorative study on the predictive value of systematic inflammatory and metabolic markers on weight loss in head and neck cancer patients undergoing radiotherapy.

Authors:  Ylva Tiblom Ehrsson; Per M Hellström; Kerstin Brismar; Lena Sharp; Ann Langius-Eklöf; Göran Laurell
Journal:  Support Care Cancer       Date:  2009-10-15       Impact factor: 3.603

8.  Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: a report from the DIGAMI 2 trial.

Authors:  Linda G Mellbin; Lars Rydén; Kerstin Brismar; Nils G Morgenthaler; John Ohrvik; Sergiu B Catrina
Journal:  Diabetes Care       Date:  2010-04-22       Impact factor: 17.152

9.  Peripheral sensory neuropathy associates with micro- or macroangiopathy: results from a population-based study of type 2 diabetic patients in Sweden.

Authors:  Lars Kärvestedt; Eva Mårtensson; Valdemar Grill; Stig Elofsson; Gunvor von Wendt; Anders Hamsten; Kerstin Brismar
Journal:  Diabetes Care       Date:  2008-11-25       Impact factor: 17.152

10.  Effects of oral contraceptives on diurnal profiles of insulin, insulin-like growth factor binding protein-1, growth hormone and cortisol in endurance athletes with menstrual disturbance.

Authors:  A Rickenlund; M Thorén; A Nybacka; J Frystyk; A Lindén Hirschberg
Journal:  Hum Reprod       Date:  2009-10-19       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.